Literature DB >> 7671613

Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management.

E M Messmer1, C S Foster.   

Abstract

The onset of necrotizing scleritis (NS) and peripheral ulcerative keratitis (PUK) in the clinical course of rheumatoid arthritis (RA) may reflect the presence of systemic, potentially lethal vasculitis. In an effort to better characterize this subset of patients with severe RA-associated corneal and/or scleral inflammation and to analyze the efficacy of therapy, we reviewed our experience in the medical and surgical management of 16 tertiary referral cases (25 eyes) unresponsive to aggressive conventional therapy with topical and systemic steroids as well as with systemic nonsteroidal drugs. Cytotoxic immunosuppressive therapy was instituted in all patients with NS and/or PUK. Cyclophosphamide and methotrexate were the most successful agents used. Cytotoxic immunosuppressive drugs in conjunction with early aggressive surgical treatment halted the relentlessly progressive inflammation and preserved the integrity of the globe in 92% of eyes. Visual acuity could be stabilized or improved in 83% of patients with NS and in 68% of patients with PUK.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671613     DOI: 10.1097/00003226-199507000-00010

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  21 in total

1.  Ophthaproblem. Peripheral corneal thinning secondary to rheumatoid arthritis.

Authors:  J Cheung; S Sharma
Journal:  Can Fam Physician       Date:  2000-09       Impact factor: 3.275

2.  Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease.

Authors:  K B Baker; N J Spurrier; A S Watkins; J R Smith; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

Review 3.  Inflammatory conditions of the eye associated with rheumatic diseases.

Authors:  N A Afshari; M A Afshari; C S Foster
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

4.  A role for methotrexate in the management of non-infectious orbital inflammatory disease.

Authors:  J R Smith; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

5.  Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7.

Authors:  M McKibbin; J D Isaacs; A J Morrell
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

Review 6.  Ocular inflammatory diseases associated with rheumatoid arthritis.

Authors:  Mathieu Artifoni; Pierre-Raphaël Rothschild; Antoine Brézin; Loïc Guillevin; Xavier Puéchal
Journal:  Nat Rev Rheumatol       Date:  2013-12-10       Impact factor: 20.543

7.  Corneal melting in rheumatoid arthritis patients treated with a tectonic reinforcing corneolimbal graft: an interventional case series.

Authors:  Eitan Livny; Michael Mimouni; Irit Bahar; Yair Molad; Assaf Gershoni; Israel Kremer
Journal:  Int Ophthalmol       Date:  2017-04-21       Impact factor: 2.031

8.  Cyclophosphamide for ocular inflammatory diseases.

Authors:  Siddharth S Pujari; John H Kempen; Craig W Newcomb; Sapna Gangaputra; Ebenezer Daniel; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; C Stephen Foster
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

Review 9.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 10.  Scleritis and peripheral ulcerative keratitis.

Authors:  Anat Galor; Jennifer E Thorne
Journal:  Rheum Dis Clin North Am       Date:  2007-11       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.